Tong Ren Tang Technologies subsidiary Tong Ren Tang Chinese Medicine posts 2025 profit of HKD 416.86 million

Reuters

Mar 20

<a href="https://laohu8.com/S/TGRNF">Tong Ren Tang Technologies</a> subsidiary <a href="https://laohu8.com/S/01666">Tong Ren Tang</a> Chinese Medicine posts 2025 profit of HKD 416.86 million

Tong Ren Tang Chinese Medicine, a subsidiary of Tong Ren Tang Technologies, reported revenue of HKD 1.51 billion, compared with HKD 1.61 billion.
Profit for the year was HKD 416.86 million, versus HKD 529.17 million.
Basic and diluted earnings per share were HKD 0.47, compared with HKD 0.6.
Total assets were HKD 4.66 billion, compared with HKD 4.56 billion.
Cash and cash equivalents were HKD 2.23 billion, versus HKD 1.77 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tong Ren Tang Technologies Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260320-12061466), on March 20, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620739697"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620739697\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620739697?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620739697","market":"fut","top_or_hot":-1,"title":"Tong Ren Tang Technologies subsidiary Tong Ren Tang Chinese Medicine posts 2025 profit of HKD 416.86 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TGRNF\">Tong Ren Tang Technologies</a> subsidiary <a href=\"https://laohu8.com/S/01666\">Tong Ren Tang</a> Chinese Medicine posts 2025 profit of HKD 416.86 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Tong Ren Tang Chinese Medicine, a subsidiary of Tong Ren Tang Technologies, reported revenue of HKD 1.51 billion, compared with HKD 1.61 billion.\n        </li>\n<li>\n          Profit for the year was HKD 416.86 million, versus HKD 529.17 million.\n        </li>\n<li>\n          Basic and diluted earnings per share were HKD 0.47, compared with HKD 0.6.\n        </li>\n<li>\n          Total assets were HKD 4.66 billion, compared with HKD 4.56 billion.\n        </li>\n<li>\n          Cash and cash equivalents were HKD 2.23 billion, versus HKD 1.77 billion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tong Ren Tang Technologies Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260320-12061466), on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tong Ren Tang Technologies subsidiary Tong Ren Tang Chinese Medicine posts 2025 profit of HKD 416.86 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTong Ren Tang Technologies subsidiary Tong Ren Tang Chinese Medicine posts 2025 profit of HKD 416.86 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TGRNF\">Tong Ren Tang Technologies</a> subsidiary <a href=\"https://laohu8.com/S/01666\">Tong Ren Tang</a> Chinese Medicine posts 2025 profit of HKD 416.86 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Tong Ren Tang Chinese Medicine, a subsidiary of Tong Ren Tang Technologies, reported revenue of HKD 1.51 billion, compared with HKD 1.61 billion.\n        </li>\n<li>\n          Profit for the year was HKD 416.86 million, versus HKD 529.17 million.\n        </li>\n<li>\n          Basic and diluted earnings per share were HKD 0.47, compared with HKD 0.6.\n        </li>\n<li>\n          Total assets were HKD 4.66 billion, compared with HKD 4.56 billion.\n        </li>\n<li>\n          Cash and cash equivalents were HKD 2.23 billion, versus HKD 1.77 billion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tong Ren Tang Technologies Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260320-12061466), on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL6bBw6M:1","article_id":"2620739697","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620739697","pubTimestamp":1774012021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tong Ren Tang Chinese Medicine, a subsidiary of Tong Ren Tang Technologies, reported revenue of HKD 1.51 billion, compared with HKD 1.61 billion.Profit for the year was HKD 416.86 million, versus HKD 529.17 million.Basic and diluted earnings per share were HKD 0.47, compared with HKD 0.6.Total assets were HKD 4.66 billion, compared with HKD 4.56 billion.Cash and cash equivalents were HKD 2.23 billion, versus HKD 1.77 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tong Ren Tang Technologies Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 20, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600085":"同仁堂","BK0196":"行业龙头","BK0188":"融资融券","01666":"同仁堂科技","BK0097":"医药电商","BK0028":"国家队","BK1583":"高瓴概念","BK0239":"医药制造","BK0113":"养老产业","BK0086":"举牌","BK0183":"MSCI概念","03613":"同仁堂国药","LU1688375341.USD":"贝莱德中国灵活股票基金","BK1515":"抗疫概念","BK1191":"制药","BK1606":"中医药概念","BK0012":"证金概念"},"translate_title":"同仁堂科技子公司同仁堂中药2025年盈利41686万港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600085":0.9,"03613":0.9,"01666":0.9},"content_text":"Tong Ren Tang Technologies subsidiary Tong Ren Tang Chinese Medicine posts 2025 profit of HKD 416.86 million\n    \n\n\n          Tong Ren Tang Chinese Medicine, a subsidiary of Tong Ren Tang Technologies, reported revenue of HKD 1.51 billion, compared with HKD 1.61 billion.\n        \n\n          Profit for the year was HKD 416.86 million, versus HKD 529.17 million.\n        \n\n          Basic and diluted earnings per share were HKD 0.47, compared with HKD 0.6.\n        \n\n          Total assets were HKD 4.66 billion, compared with HKD 4.56 billion.\n        \n\n          Cash and cash equivalents were HKD 2.23 billion, versus HKD 1.77 billion.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tong Ren Tang Technologies Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260320-12061466), on March 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}